July's death of a patient in Targeted Genetics Inc.'s halted Phase I/II trial of the arthritis drug tgAAC94 shone the spotlight - unfavorably, again - on gene therapy, dragging all involved companies out for inspection. And it gave many investors an excuse to talk about China, as if many in biotech weren't already. (BioWorld Financial Watch) Read More
